Robert Driscoll, PH.D.

ANALYST BIOGRAPHY

Robert Driscoll, Ph.D., has over a decade in research and analytics in the life sciences sector – specifically in the area of oncology and more recently in the areas of infectious disease. He is a molecular biologist who received his Ph.D. from the University of Cambridge, and spent six additional years working in the lab at Stanford. He is particularly interested in the development and causes of cancer, as well as the expanding world of immuno-oncology. Since joining Wedbush in 2014, Robert has been covering a number of cutting-edge companies that include Arvinas (ARVN), Kura Oncology (KURA), Arcus Biosciences (RCUS), and IGM Biosciences (IGMS).

Robert received his Bachelor’s degree in Biochemistry from the University of Leeds, and his Ph.D. in Cellular and Molecular Biology from the University of Cambridge. He also completed a postdoctoral fellowship at Stanford University.

ANALYST EDGE

Robert’s Edge: His biochemistry, cellular and molecular biology background allows for Robert to decipher the intricacies of the science behind biopharmaceuticals. It is this understanding that gives him insight into how biotech companies are working to extend the durability and breadth of patient responses to immuno-oncology treatments. He is also adept at connecting the dots between the novel scientific research to effective targeted therapies in development.

COMPANIES UNDER COVERAGE